Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$265.58-0.77 (-0.29%)
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Sep 11, 2026, 4:00 PM EDT
Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 22.99 as of 2026-09-14T13:20:46.727Z.
Consensus retrieved: 2026-09-13T23:03:48.704Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-14T13:20:46.727Z.
Quote observation: 2026-09-11T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c5d71939891d50f43b477f3dd23b47cf8ea98804d756fac9b811a8bcf6d5e23f
Forward PE Ratio (22.99) = Dated Quote Price ($265.58) / Consensus Forward EPS ($11.55)
FORWARD PE RATIO
22.99
SECTOR MEDIAN · HEALTHCARE
18.99
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+21.06%
vs the sector median at left
Johnson & Johnson
Market Cap
$640.02B
Forward PE Ratio
22.99
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Johnson & Johnson (JNJ) | $640.02B | 22.99 |
| Pfizer Inc. (PFE)vs › | $157.99B | 9.32 |
| Merck & Co., Inc. (MRK)vs › | $355.49B | 52.41 |
| AbbVie Inc. (ABBV)vs › | $454.17B | 18.30 |
| Eli Lilly and Company (LLY)vs › | $1.05T | 30.65 |
| Bristol-Myers Squibb Company (BMY)vs › | $130.00B | 9.18 |
Trailing P/E
30.8
reported TTM EPS
Forward P/E
23.0
consensus EPS · fiscal year ending 2026-12-28
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $11.55 implies +33.8% EPS growth vs the reported trailing $8.63.
At the dated quote price of $265.58, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-28 | $11.55 | $10.98 – $11.85 | 5 | 23.0x |
| 2027-12-28 | $12.78 | $12.23 – $13.52 | 5 | 20.8x |
| 2028-12-28 | $14.31 | $14.13 – $14.48 | 1 | 18.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute